01—Abstract
Summary
Summary of the 8-K filed February 21, 2025. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. (the "Company") disclosed in this Form 8-K, filed February 21, 2025, that Chair, President and CEO James C.
Foster and Corporate Executive Vice President and Chief Operating Officer Birgit Girshick each bought shares of Company common stock in open market transactions on February 20, 2025. Mr. Foster purchased 6,075 shares at an average price of $165.01a, for an aggregate purchase price of approximately $1 million. Ms. Girshick purchased 1,514 shares at an average price of $164.63, for an aggregate purchase price of approximately $250,000.
Both executives said the purchases reflect their confidence in the Company's strategic direction and long-term growth prospects. Before making these purchases, both executives terminated their Rule 10b5-1 trading plans on February 19, 2025, so that the buys would not unintentionally violate Section 16 short-swing profit rules through open market sales within six months of purchases. Mr. Foster's terminated plan, dated February 26, 2024, allowed for the sale of a maximum of 129,721 shares, and he sold 25,000 shares under it on August 1, 2024.
Ms. Girshick's terminated plan, dated November 22, 2023, allowed for the sale of a maximum of 22,362 shares, and the filing states she did not sell any shares under it. The purchases will be reported separately on Forms 4.
The filing is an Item 8.01 (Other Events) disclosure and contains no financial results, guidance, or operational updates. It refers to the Company's Annual Report on Form 10-K filed February 19, 2025, for risks relating to the Company, and includes standard forward-looking statement language.
02—Key points
Key Highlights
- Chair, President and CEO James C. Foster bought 6,075 shares of common stock on February 20, 2025, at an average price of $165.01 (about $1 million in aggregate).
- Corporate Executive Vice President and COO Birgit Girshick bought 1,514 shares on February 20, 2025, at an average price of $164.63 (about $250,000 in aggregate).
- Both executives cited confidence in the Company's strategic direction and long-term growth prospects as the reason for the purchases.
- Both executives terminated their Rule 10b5-1 trading plans on February 19, 2025, to avoid Section 16 short-swing profit rule conflicts with the open market purchases.
- Mr. Foster's terminated plan, dated February 26, 2024, covered a maximum of 129,721 shares; he sold 25,000 shares under it on August 1, 2024.
- Ms. Girshick's terminated plan, dated November 22, 2023, covered a maximum of 22,362 shares; the filing states she sold no shares under it.
- The insider purchases will be reported separately on Forms 4 filed with the SEC.
03—Questions
Frequently Asked Questions
Who bought Charles River Laboratories stock, and how much did they spend?
CEO James C. Foster bought 6,075 shares at an average price of $165.01, for about $1 million. COO Birgit Girshick bought 1,514 shares at an average price of $164.63, for about $250,000. Both purchases were made in open market transactions on February 20, 2025.
Why did the executives buy shares?
Both Mr. Foster and Ms. Girshick said the purchases reflect their confidence in the Company's strategic direction and long-term growth prospects.
Why did the executives terminate their trading plans before buying?
The Rule 10b5-1 plans allowed scheduled share sales. Terminating them allowed the executives to buy shares without unintentionally violating Section 16 short-swing profit rules, which bar matching open market sales within six months of purchases.
Did the executives sell shares under the terminated plans?
Mr. Foster sold 25,000 shares under his plan (maximum 129,721 shares) on August 1, 2024. The filing states Ms. Girshick did not sell any shares under her plan (maximum 22,362 shares).
Does this filing contain financial results or guidance?
No. The filing is an Item 8.01 Other Events disclosure about insider share purchases and trading plan terminations. It contains no financial results or guidance and refers to the Company's Form 10-K filed February 19, 2025, for risk factors.
04—Continue